A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment
|Christina Susanne Mullins1,2, Björn Schneider3, Anne Lehmann2, Florian Stockhammer4, Sascha Mann4, Carl-Friedrich Classen1 and Michael Linnebacher2*|
|1University Children’s Hospital, University Medicine Rostock, Germany|
|2Department of General Surgery, University Medicine Rostock, Germany|
|3Institute for Pathology, University Medicine Rostock, Germany|
|4Department of Neurosurgery, University Medicine Rostock, Germany|
|Corresponding Author :||Michael Linnebacher, PhD, PI
Group leader, University Rostock, General Surgery
Schillingallee 69, Rostock, MV 18057, Germany
E-mail: [email protected]
|Received November 07, 2013; Accepted January 03, 2014; Published May 25, 2014|
|Citation: Mullins CS, Schneider B, Lehmann A, Stockhammer F, Mann S, et al. (2014) A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment. J Cancer Sci Ther 6:177-187. doi:10.4172/1948-5956.1000269|
|Copyright: © 2014 Mullins CS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Patient-individual tumor models for Glioblastoma Multiforme (GBM) are important not only for basic and translational research but also for the development and improvement of optimal and individualized treatment strategies. The model that has gained widest acceptance is the primary cell culture model. The laborious and time consuming process is rewarded with a relative high initial success rate (about 60%). We here describe and evaluate an extended biobanking methodology to simplify sample collection and model establishment. GBM resection specimen were collected ad hoc, partially prepared fresh for modeling, snap frozen for molecular testing and frozen down vitally.
The established models were subject to subsequent detailed characterization in direct comparison to the patients´ tumors. Generally, molecular characteristics such as mutations, gene amplifications and epigenetic alterations were maintained in the models. Immortality, neuronal origin and stem cell characteristics of the cell lines could be demonstrated. Extensive drug sensitivity screens were performed. These well-defined patient-individual models are ideal for establishment of individualized therapy approaches and enable testing of immunological strategies.
Our extended biobanking procedure facilitates collection, long-time storage and propagation (modeling) of clinical GBM specimens (potentially also from distant centers) for basic research, (pre-) clinical studying of novel therapies and individual response prediction.